These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1130 related articles for article (PubMed ID: 25012047)
21. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391 [TBL] [Abstract][Full Text] [Related]
22. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972 [TBL] [Abstract][Full Text] [Related]
23. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923 [TBL] [Abstract][Full Text] [Related]
24. Is there a low-grade precursor pathway in breast cancer? King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747 [TBL] [Abstract][Full Text] [Related]
25. Hormone receptor-negative breast cancer: undertreatment of patients over 80. Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924 [TBL] [Abstract][Full Text] [Related]
26. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein. Recăreanu F; Simionescu C; Georgescu CV; Pirici E Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825 [TBL] [Abstract][Full Text] [Related]
27. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer. Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698 [TBL] [Abstract][Full Text] [Related]
28. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Sughayer MA; Al-Khawaja MM; Massarweh S; Al-Masri M Pathol Oncol Res; 2006; 12(2):83-6. PubMed ID: 16799708 [TBL] [Abstract][Full Text] [Related]
29. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting. Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064 [TBL] [Abstract][Full Text] [Related]
30. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737 [TBL] [Abstract][Full Text] [Related]
31. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis. Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349 [TBL] [Abstract][Full Text] [Related]
32. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455 [TBL] [Abstract][Full Text] [Related]
33. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Caldarella A; Crocetti E; Bianchi S; Vezzosi V; Urso C; Biancalani M; Zappa M Pathol Oncol Res; 2011 Sep; 17(3):753-8. PubMed ID: 21479875 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India. Singh R; Gupta S; Pawar SB; Pawar RS; Gandham SV; Prabhudesai S J Cancer Res Ther; 2014; 10(1):26-8. PubMed ID: 24762482 [TBL] [Abstract][Full Text] [Related]
35. Morphological profile and receptor status in breast carcinoma: an institutional study. Rao C; Shetty J; Kishan Prasad HL J Cancer Res Ther; 2013; 9(1):44-9. PubMed ID: 23575073 [TBL] [Abstract][Full Text] [Related]
36. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214 [TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696 [TBL] [Abstract][Full Text] [Related]
38. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma. El-Hafez AA; El Aaty Shawky A; Hasan B Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005 [TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience. Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617 [TBL] [Abstract][Full Text] [Related]
40. Pathology of Senegalese breast cancers. Fitzpatrick MB; Rendi MH; Kiviat NB; Toure P; Dem A; Sow PS; Hawes SE; Feng Q; Allison KH Pan Afr Med J; 2019; 34():67. PubMed ID: 31819783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]